The LiBBY Phase II result is a genuine proof-of-concept signal in an indication with no approved pharmacological standard, but the announcement withholds virtually every parameter needed to assess clinical meaningfulness. No sample size, no effect size, no safety data, no formulation composition, and no comparator arm are disclosed — gaps that are not incidental but determinative for regulatory and payer decisions. The sharpest precedent is the 2021 Cochrane review of cannabinoids in dementia (four trials, 126 participants), which concluded evidence was of low-to-very-low certainty and that any benefits, if present, 'may be too small to be clinically meaningful.' That precedent directly maps to LiBBY: a positive signal on a behavioral scale does not establish clinical significance. A second controlling precedent is the NICE TA615/TA614 framework for cannabidiol in Lennox-Gastaut and Dravet syndromes, where approval required multi-year open-label extension data, explicit stopping rules anchored to a 30% improvement threshold at six months, and comprehensive caregiver quality-of-life endpoints — none of which are present in LiBBY's 12-week dataset. [1] On the peer landscape, brexpiprazole received FDA approval for AD agitation following three RCTs with active comparator arms; dextromethorphan combinations are in Phase 2/3; nabiximols (STAND trial, n=29) is a direct cannabinoid competitor in AD agitation that demonstrated feasibility but has not yet reported efficacy outcomes. [2][3] The market access signal from NICE NG144 is unambiguous: cannabis-based medicinal products were rejected for chronic pain despite statistical efficacy because a 0.4-point improvement on a 10-point scale did not justify ongoing costs — a direct warning that statistical significance without effect-size disclosure invites a comparable HTA outcome here. [4] The 2026 meta-analysis (10 studies, 328 participants, SMD -0.52) is the most contemporaneous aggregate estimate, but it loses significance after removal of high-risk-of-bias studies (SMD -0.35, p=0.1), underscoring the fragility of the aggregate cannabinoid evidence base. [5] The sharpest risk is that LiBBY's undisclosed effect size may sit within the range the Cochrane review called clinically unmeaningful, leaving the entire regulatory narrative contingent on a number the company has not released.
Primary endpoint met but sample size, effect magnitude, confidence intervals, safety profile, and formulation details are all withheld. The 2021 Cochrane review of cannabinoids in dementia (126 participants, low-to-very-low certainty) and the 2026 meta-analysis (SMD -0.35, p=0.1 after bias removal) establish that positive cannabinoid signals in this population have repeatedly failed to survive quality adjustment. [5]
| Indication | Agitation in advanced dementia |
| Drug | THC and CBD |
| Company | MediPharm Labs Corp. |
| Trial Phase | Phase II |
| Trial Acronym | LiBBY |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Neuroscience |
| Conference Name | Alzheimer’s Association International Conference (AAIC) |
| Presentation Date | July 14, 2026 |
| Study Design | Randomized, double-blind, placebo-controlled |
| Primary Endpoint Measure | Cohen-Mansfield Agitation Inventory (CMAI) |
| Treatment Period | 12 weeks |
| Funding Sources | National Institute on Aging, U.S. National Institutes of Health, Alzheimer’s Association |
| Coordinating Institution | USC Epstein Family Alzheimer’s Therapeutic Research Institute (ATRI) |
| Patient Population | Hospice-eligible patients with Alzheimer’s disease or other dementias |
| Company Certifications | US FDA-registered facility, Drug Establishment Licence, EU-GMP certification, ANVISA GMP certification, TGA compliance |
MediPharm Labs' LiBBY Trial Shows Significant Agitation Reduction in Dementia
MediPharm Labs Corp. announced positive results from its Phase II LiBBY clinical trial, evaluating a proprietary oral cannabinoid formulation for treating agitation in patients with advanced dementia. The study successfully met its primary endpoint, demonstrating statistically significant improvements in agitation symptoms compared to placebo. Benefits were observed as early as two weeks and sustained throughout the 12-week treatment period. These findings were presented at the Alzheimer’s Association International Conference (AAIC) in London, United Kingdom. MediPharm Labs developed and supplied the formulation, retaining ownership and rights to the study data for future regulatory submissions and development.
- The LiBBY study successfully met its primary endpoint, demonstrating a statistically significant improvement in agitation symptoms as early as two weeks, measured by the Cohen-Mansfield Agitation Inventory (CMAI). These benefits were consistently sustained throughout the entire 12-week double-blind treatment period, indicating a durable therapeutic effect for patients with advanced dementia.
- Beyond the primary endpoint, the trial also observed statistically significant improvements in overall clinical status when compared to placebo. Furthermore, supportive findings from the optional open-label extension phase reinforced the durability of the response, suggesting continued patient benefit over a longer duration and supporting the long-term potential of the formulation.
- MediPharm Labs developed and supplied the proprietary oral cannabinoid formulation, retaining full ownership of the intellectual property and rights to utilize the study data. This positions the company to pursue future regulatory activities, additional clinical development opportunities, and potential strategic collaborations, leveraging the positive results to advance cannabinoid-based medicines for unmet needs in dementia care.
LiBBY Trial: Positive Phase II Outcomes for Cannabinoid Formulation
Recent clinical investigation into agitation in advanced dementia has yielded meaningful data across both pharmacological and non-pharmacological modalities. The studies below — spanning randomized controlled trials, systematic reviews, and meta-analyses published in 2025–2026 — provide a current snapshot of the evidence base informing treatment strategy.
| Study Name | Intervention | Key Efficacy Outcomes | Key Safety Outcomes |
|---|---|---|---|
| Pooled analysis of two Phase 3, 12-week, multicenter, RDBPCTs (NCT01862640, NCT03548584) | Brexpiprazole 2 or 3 mg/day (fixed-dose) vs. placebo; N=621 (brexpiprazole n=368, placebo n=253) | LS mean CMAI total score improvement: −22.8 vs. −18.3 points (LS mean difference: −4.50; 95% CI −6.90 to −2.10; p<0.001; Cohen's d=0.30); greater improvement also observed on CGI-S and all CMAI factor scores; numerically greater agitation reduction in 12 of 13 subgroups | No significant between-group differences in adverse event incidence; TEAEs generally consistent across subgroups; reported events include nasopharyngitis, UTI, dizziness, somnolence, headache, and insomnia; gradual dose escalation recommended |
| Systematic review with exploratory meta-analysis of ECT for agitation and/or aggression in dementia (2026) | Electroconvulsive therapy (ECT); 13 studies, N=206 patients with dementia | Response rates typically 70–90%; pooled clinical response proportion: 77.7% (95% CI 71.0–83.3%); sensitivity analysis (n≥5): 81.2% (95% CI 71.7–88.0%); improvement typically emerged within 2–4 treatments (median=3 sessions); reductions confirmed via CMAI and Pittsburgh Agitation Scale | Generally well tolerated; adverse effects mostly mild and transient; no treatment-related deaths or persistent severe complications reported |
| Taiwan Consensus on Pharmacological Management — evidence-based review with expert consensus (integrating evidence to June 2025) | Multiple agents reviewed: brexpiprazole, risperidone, aripiprazole, citalopram, agomelatine, anticonvulsants, acetylcholinesterase inhibitors, memantine | Brexpiprazole demonstrated strongest evidence and most favorable safety profile; risperidone and aripiprazole effective but require monitoring; citalopram and agomelatine preferred when safety is prioritized; anticonvulsants, AChEIs, and memantine show limited efficacy | Risperidone and aripiprazole require monitoring for cerebrovascular and extrapyramidal risks; long-term or routine pharmacological use not supported by current evidence |
| Systematic review and meta-analysis of Need-Driven Dementia-Compromised Behavior (NDB) model-based interventions (2026) | Individualized non-pharmacological interventions based on NDB model criteria: recognition of behavior as expression, assessment of background/proximal factors, individualized care plan; 22 studies, N=733 participants | Significant reductions in overall BPSD (SMD=−0.308; 95% CI −0.589 to −0.027); agitation (SMD=−0.391; 95% CI −0.670 to −0.111); depression (SMD=−0.431; 95% CI −0.792 to −0.071); indoor/outdoor setting and social interaction were significant moderators of agitation effect size | Safety outcomes not formally reported in included studies |
| Meta-analysis of nature-based interventions for agitation in dementia (2025) | Nature-based interventions (direct and indirect exposure to natural elements); 29 studies, N=733 participants aged ≥65 in long-term residential care | Significant reduction in agitation (negative mean effect size); indoor vs. outdoor setting and presence of social interaction were significant predictors of effect size; no significant difference by nature exposure type (direct vs. indirect) or intervention duration | No serious adverse events reported across included studies |
| Systematic review of touch-based therapies for agitation in dementia (2026) | Massage (n=21 studies), acupressure (n=8), therapeutic/healing touch (n=3), reflexology/shiatsu (n=2); sessions typically 5–20 minutes, several times/week for 2–6 weeks | Most consistent finding: short-term calming and agitation reduction immediately post-session or over brief treatment courses; clearest pattern for massage and acupressure; effects on broader NPI domains and pain were mixed | No serious adverse events reported; minor transient issues (brief restlessness, skin sensitivity with aromatherapy oils) infrequent; acceptability generally high; durability beyond 4–8 weeks rarely assessed |
| Double-blind, placebo-controlled crossover trial of nabilone in moderate-to-severe Alzheimer's disease (2026) | Nabilone (cannabinoid); N=39 participants (77% male, mean age 87 years, sMMSE 6.5) | Medium effect size for agitation reduction; five characteristics predicted greater response: higher pain (PAINAD ≥3; CMAI difference=−18.8), greater appetite/eating disorders (−16.4), greater apathy (−14.0), less cognitive impairment (sMMSE >10; −16.5), no concomitant cholinesterase inhibitors (−13.9); response rates: 82% (top tertile) vs. 40% (lowest tertile); treatment-by-tertile interaction F(2,29)=8.48, p=0.001 | Data from crossover trial design; specific adverse event profile not detailed in available summary |
MediPharm's Cannabinoid: Shifting the Agitation Treatment Landscape
Published clinical evidence reveals a treatment landscape for agitation in advanced dementia dominated by antipsychotic agents — both typical and atypical — alongside a growing body of data on alternative pharmacological approaches, including antidepressants and the recently FDA-approved brexpiprazole. While these agents demonstrate measurable efficacy signals, effect sizes remain modest across drug classes, and safety concerns — particularly mortality, cerebrovascular risk, and extrapyramidal symptoms — continue to constrain their clinical utility.
| Agent / Class | Study Design | Key Efficacy Findings | Key Safety Findings | Evidence Certainty |
|---|---|---|---|---|
| Atypical antipsychotics (pooled) | Cochrane review, 24 RCTs, n = 6,090 (2022) | Slight reduction in agitation (SMD −0.21, 95% CI −0.30 to −0.12); negligible effect on psychosis (SMD −0.11, 95% CI −0.18 to −0.03) | Somnolence (RR 1.93), extrapyramidal symptoms (RR 1.39), serious adverse events (RR 1.32), increased mortality (RR 1.36) | Moderate (agitation, EPS, SAEs); High (somnolence) |
| Typical antipsychotics (pooled) | Cochrane review, 24 RCTs, n = 6,090 (2022) | May slightly improve psychosis (SMD −0.29, 95% CI −0.55 to −0.03); uncertain effect on agitation (SMD −0.36, 95% CI −0.57 to −0.15) | Somnolence (RR 2.62), extrapyramidal symptoms (RR 2.26), possible increase in SAEs (RR 1.32) and death (RR 1.46) | Low to very low (agitation); High (EPS) |
| Risperidone vs. placebo | 12-week RCT, n = 345, mean dose 0.95 mg/day (2003) | Significant reduction in CMAI aggression score (p <.001); BEHAVE-AD total (p <.001); CGI-S and CGI-C improvement (p <.001) | Somnolence and UTI more frequent vs. placebo; EPS rate not significantly different (23% vs. 16%) | Individual RCT |
| Risperidone vs. haloperidol vs. placebo | 13-week double-blind RCT, n = 344, mean doses: risperidone 1.1 mg/d, haloperidol 1.2 mg/d (1999) | BEHAVE-AD total and CMAI aggression cluster scores significantly reduced vs. placebo at week 12; greater BEHAVE-AD aggressiveness reduction with risperidone vs. haloperidol (post hoc) | EPS severity with risperidone not significantly different from placebo; lower than haloperidol | Individual RCT |
| Haloperidol (pooled) | Systematic review, 5 RCTs (2002) | No consistent improvement in agitation vs. placebo; some evidence for aggression control at higher doses (>2 mg/day) | Frequent adverse events and higher dropout rates vs. placebo; Parkinsonian symptoms (rigidity, bradykinesia) at higher doses or prolonged use | Low |
| Brexpiprazole | FDA-approved May 2023; multiple RCTs including 14-week Japanese cohort | Effective for agitation in AD at 2–3 mg/day; separation from placebo at 6–12 weeks; mean CMAI change −4.0 (SD 9.8) at week 14 in Japanese cohort; particularly beneficial in severe agitation/aggression | 90.2% treatment-emergent adverse event incidence (mostly mild-moderate); no new safety signals; 71.3% study completion rate | Moderate; small effect sizes |
| Citalopram (SSRI) | 12-week RCT (CitAD trial) in nondepressed dementia patients | Positive effect on agitation (NBRS-A); composite effect size 0.53 (95% CI 0.22–0.83) vs. 0.32 for NBRS-A (95% CI 0.01–0.62) | 5-HTTLPR low-expression alleles (S and Lg) predicted greater side effects and early discontinuation; potential pharmacogenomic biomarker utility | Individual RCT |
| Mirtazapine | 12-week open-label study, n = 16, doses 15–30 mg/day (2019) | Significant reduction in CMAI-SF and CGI-S (p <.001); mean CMAI-SF reduction of 10.6 (±7.5) from baseline of 26.54 (±5.4) | No significant side effects or cognitive deterioration reported | Low (open-label, small n) |
| Mirtazapine | 12-week RCT, n = 204 (2022) | No significant difference vs. placebo on mean CMAI scores | No cost-effectiveness advantage over placebo; groups did not differ on quality of life measures | Moderate |
| Carbamazepine / Valproate | Controlled and uncontrolled studies (1998) | Carbamazepine: positive results in two larger controlled studies; valproate: efficacy in uncontrolled studies only | Not formally characterized in reviewed evidence | Low |
| Benzodiazepines | 2 RCTs included in 2019 systematic review | Only lorazepam showed improvement in one trial | Limited evidence base | Very low |
| Melatonin agonists | 6 RCTs in 2019 systematic review | No efficacy demonstrated outside of improved sleep measures | — | Low |
| Pimavanserin / Dextromethorphan-quinidine | Single trial each (as of 2019 systematic review) | Both showed benefit in their respective trials | Limited to single-study evidence | Low |
A Pivotal Advance for Cannabinoids in Dementia Agitation
Agitation in advanced dementia represents one of the most challenging and distressing neuropsychiatric symptoms, profoundly impacting both patients and their caregivers. Current pharmacological options, primarily atypical antipsychotics, offer limited benefits and are associated with significant side effects, including increased mortality risk, underscoring a critical unmet medical need. Non-pharmacological interventions remain the first-line approach, but effective pharmacological alternatives are desperately sought.
In this context, MediPharm Labs' announcement of positive Phase II results for its proprietary oral cannabinoid formulation in treating agitation in advanced dementia is a significant development. The trial successfully met its primary endpoint, demonstrating statistically significant improvements in agitation symptoms that were observed early and sustained. This outcome provides crucial validation for the potential of cannabinoid-based therapies in this specific, high-need indication.
However, the path forward is not without its considerations. While cannabinoids have shown promise in various studies for neuropsychiatric symptoms like agitation, sleep disturbances, and weight management in dementia, the overall quality of evidence has often been rated as low, with some high-quality trials failing to show significant improvement. Key risks to consider include:
Replication in larger trials: The positive Phase II findings will need robust replication in larger, well-controlled Phase III studies to confirm efficacy and safety, especially given the historical inconsistencies in cannabinoid research.
Dose optimization and sedation: While efficacy may be dose-dependent, higher doses of cannabinoids have been linked to an increased risk of sedation, a critical adverse event in vulnerable elderly populations. Careful dose titration will be essential.
Regulatory and market access hurdles: Navigating the complex regulatory landscape for cannabinoid-derived medicines, particularly in regions where cannabis remains a controlled substance, will require demonstrating a clear and compelling benefit-risk profile against existing treatment paradigms.
Despite these challenges, the positive Phase II data marks a pivotal step, offering new hope for patients and caregivers grappling with advanced dementia agitation. Continued rigorous research, careful dose optimization, and strategic navigation of regulatory pathways will be essential to bring this promising therapy to those who desperately need it.
Frequently Asked Questions
References
- [1] Lichwala K, Szukalska S et al.. Multimodal Management of Aggression in Dementia Among Geriatric Patients: A Comprehensive Overview With Particular Emphasis on Pharmacotherapy and Behavioral Interventions. Cureus. 2026 Jan. 41717150
- [2] O'Hara-Veintimilla K, González J et al.. All-Cause Mortality Associated with Antipsychotic Use in People Living with Dementia and Neuropsychiatric Symptoms: Secondary Analysis of a Systematic Review and Meta-Analysis. Dementia and geriatric cognitive disorders. 2026 Feb 10. 41666145
- [3] Shaukat A, Riaz R et al.. Brexpiprazole: Pioneering medication for managing agitation in Alzheimer's disease. Journal of Alzheimer's disease reports. 2025 Jan-Dec. 40969221
- [4] O'Hara-Veintimilla K, Borda MG et al.. Treatment-Resistant Neuropsychiatric Symptoms in Dementia: Development of a Conceptual Framework. Journal of the American Medical Directors Association. 2026 Mar. 41519503
- [5] Trifirò G, Spina E et al.. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?. Pharmacological research. 2009 Jan. 18977443
- [6] Cheng CM, Tsai MJ et al.. Pharmacological management of agitation in dementia: An evidence-based review with expert consensus. Journal of the Chinese Medical Association : JCMA. 2026 Mar 1. 41527161
- [7] Forlenza OV, Cretaz E et al.. [The use of antipsychotics in patients with dementia]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2008 Sep. 18833428
- [8] Dombrovski AY, Mulsant BH et al.. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. International clinical psychopharmacology. 2010 Jan. 19996755
- [9] Grossberg GT, Sabbagh MN et al.. Efficacy of Brexpiprazole on Neuropsychiatric Symptoms and Impact on Caregivers: Pooled Neuropsychiatric Inventory (NPI) Analysis in Patients With Agitation Associated With Dementia due to Alzheimer's Disease. Journal of geriatric psychiatry and neurology. 2026 Sep. 41439450
- [10] Zarei S, Colman S et al.. The Rationale and Design of Behavioral Interventions for Management of Agitation in Dementia in a Multi-Site Clinical Trial. Journal of Alzheimer's disease : JAD. 2022. 35147535
- [11] Smoller C, Schiller E et al.. Current and Emerging Pharmacological Approaches to Agitation in Alzheimer's Disease: A Narrative Review of New and Repurposed Therapies. Drugs. 2025 Nov. 40913683
- [12] Phan SV, Osae S et al.. Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA. Drugs in R&D. 2019 Jun. 31098864
- [13] Aga VM. Brexpiprazole for the Treatment of Agitation in Alzheimer's Disease Dementia: Clinical Uncertainties and the Path Forward. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2025 Mar. 39648108
- [14] Sano M, Soto M et al.. Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force. The journal of prevention of Alzheimer's disease. 2018. 29616702
- [15] Kayser S, Fallgatter A et al.. Electroconvulsive Therapy for Aggression and Agitation in Dementia: A Systematic Review With Exploratory Meta-analytic and Ethical Perspectives. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2026 Apr. 41690837
- [16] Tripathi SM, Chutia P et al.. Punding in dementia: an insight into its occurrence, clinical characteristics, treatment, and outcome. Neurodegenerative disease management. 2026 Feb 27. 41761426
- [17] Conn D, Thorpe L. Assessment of behavioural and psychological symptoms associated with dementia. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2007 Mar. 17469686
- [18] Zhu Q, Zhang H et al.. Effectiveness of animal-assisted therapy for dementia patients: An evidence mapping of randomized controlled trials, systematic reviews, and meta-analyses. Complementary therapies in medicine. 2026 Jun. 41825488
- [19] Cummings JL, Zhou Y et al.. Alzheimer's disease drug development pipeline: 2026. Alzheimer's & dementia (New York, N. Y.). 2026 Apr-Jun. 42095064
- [20] Choe EY, Lee JY et al.. Effectiveness of Nature-Based Interventions in Reducing Agitation Among Older Adults with Dementia: A Systematic Review and Meta-Analysis. Healthcare (Basel, Switzerland). 2025 Jul 17. 40724752
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
